Zai Lab Ltd.

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced The New England Journal of Medicine (NEJM) has published data from the registrational Phase 1/2 TRIDENT-1 study evaluating repotrectinib (TPX-0005) in patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancers (NSCLCs). Repotrectinib is a tyrosine kinase inhibitor (TKI) that has shown robust anti-tumor activity against ROS1+ cancers in preclinical models. In the TRIDENT-1 study,.

Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC

Zai Lab Limited Unsponsored ADR (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy Stock

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conference in January 2024: J.P. Morgan 42nd Annual Healthcare Conference Presentation: Monday, January 8, 2024, 3:45 p.m. PST Location: San Francisco A live webcast of the presentation will be available on the Investor Relations page of Zai Lab's website at ir.zailaboratory.com/webcasts-presentat.

Zai Lab Announces Participation in January Investor Conference

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2023 National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA) has been updated to include the following medicines and indications: VYVGART® (efgartigimod alfa injection) is included for the first time in the NRDL for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR.

Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China's National Reimbursement Drug List

Zai Lab Limited (NASDAQ:ZLAB ) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Christine Chiou - Senior Vice President-Investor Relations Samantha Du - Founder, Chairperson & Chief Executive Officer Josh Smiley - President & Chief Operating Officer Rafael Amado - President & Head of Global Oncology and Research & Development Harald Reinhart - President & Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases Yajing Chen - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Yigal Nochomovitz - Citigroup Anupam Rama - JPMorgan Ziyi Chen - Goldman Sachs Operator Hello, ladies and gentlemen. Thank you for standing by, and welcome to Zai Lab's Third Quarter 2023 Financial Results Conference Call.

Zai Lab Limited (ZLAB) Q3 2023 Earnings Call Transcript

SHANGHAI, China and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2023, along with recent product highlights and corporate updates.

Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates

SHANGHAI, China and CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conferences in November 2023:

Zai Lab Announces Participation in November Investor Conferences

- Company to Host Conference Call and Webcast on November 8, 2023, at 8:00 a.m. ET - Company to Host Conference Call and Webcast on November 8, 2023, at 8:00 a.m. ET

Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023

Blade Air Mobility

Rambus

The fervor around tech stocks to buy now has been palpable this year, with several household names reaching unprecedented heights. However, with such meteoric runs, many investors are left wondering which opportunities still hold genuine upside potential, especially in a market that seems, at times, overextended.

Betting Big: 3 Tech Stocks Primed for a Breakout

SHANGHAI, China and CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation for efgartigimod alfa injection (subcutaneous injection) (efgartigimod SC) for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The Breakthrough Therapy Designation for efgartigimod SC was supported by data from both global and Chinese patients enrolled in the ADHERE study.

Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China

Zai Lab Limited is a biotech company that acts as a powerful partner for other biotechs to launch drug candidates in China. They currently distribute four drugs in mainland China and have a pipeline of cancer therapies awaiting approval. ZLAB has a strong financial position with significant cash reserves and potential for future sales growth.

Zai Lab Stock: De-Risking Through Market Tapping

The company is collaborating with two other companies on a cervical cancer therapy. Zai Lab grew revenue by 45% year over year in the second quarter.

Why Shares of Zai Lab Limited Were Jumping on Tuesday

Genmab - ADR

Seagen

Zai Lab Ltd.'s American depositary receipts ZLAB, +2.47% jumped 14% premarket on Tuesday after Seagen Inc. SGEN, +0.89% and Genmab A/S GMAB, +0.24% announced that Tivdak, their treatment for cervical cancer, improved patients' overall survival in a late-stage study.

Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results

Zai Lab (ZLAB) gains on receiving Breakthrough Therapy designation for repotrectinib from the Center for Drug Evaluation of the National Medical Products Administration in China.

Zai Lab (ZLAB) Up on Breakthrough Therapy Tag for Oncology Drug

Candidate precision medicine has shown encouraging clinical activity for both ROS1-positive NSCLC and NTRK fusion-positive advanced solid tumors Candidate precision medicine has shown encouraging clinical activity for both ROS1-positive NSCLC and NTRK fusion-positive advanced solid tumors

Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China

LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

Zai Lab Limited. (NASDAQ:ZLAB ) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET Company Participants Christine Chiou - Senior Vice President of Investor Relations Yajing Chen - Chief Financial Officer Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - Chief Operating Officer Rafael Amado - President, Head of Global Oncology Research and Development Harald Reinhart - President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases Jonathan Wang - Chief Business Development Conference Call Participants Ziyi Chen - Goldman Sachs Yigal Nochomovitz - Citi Group Michael Yee - Jefferies Malcolm Kuno - JP Morgan Jonathan Chang - SVB Leerink Partners Jonathan Chang - SVB Securities Jason Liu - Credit Suisse Operator Hello, ladies and gentlemen.

Zai Lab Limited (ZLAB) Q2 2023 Earnings Call Transcript

SHANGHAI, China and CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the second quarter of 2023, along with recent product highlights and corporate updates.

Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates

LOS ANGELES, CA / ACCESSWIRE / August 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ: ZLAB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

Zai Lab Limited's recent clinical study results and partnerships demonstrate its commitment to innovation and product development, positioning it as a strong investment prospect in the pharmaceutical industry. The company's partnership with MediLink and the development of YL212, a next-generation antibody-drug conjugate, further strengthen its oncology pipeline and lung cancer product line. Despite a net loss, Zai Lab retains a substantial amount of cash and cash equivalents, short-term investments, and restricted cash, placing it in a strong position for further expansion and investment opportunities.

Zai Lab: LUNAR Trial Paves Way For New Therapies

LOS ANGELES, CA / ACCESSWIRE / July 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or "the Company") (NASDAQ:ZLAB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm

- Company to Host Conference Call and Webcast on August 8, 2023, at 8:00 a.m. ET - Company to Host Conference Call and Webcast on August 8, 2023, at 8:00 a.m. ET

Zai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023

The Phase 3 PRIME study demonstrates that treatment with ZEJULA significantly extends progression-free survival versus placebo and reduces the risk of disease progression or death by 55%     Findings confirm the benefit of ZEJULA monotherapy as first-line maintenance treatment, regardless of residual disease or biomarker status, in patients with newly diagnosed advanced ovarian cancer

JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients

SHANGHAI, China and CAMBRIDGE, Mass., July 17, 2023 (GLOBE NEWSWIRE) --  Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx SE (Euronext & Nasdaq: ARGX) today announced positive topline results from the ADHERE study evaluating VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). The study met its primary endpoint (p=0.000039), demonstrating a significantly lower risk of relapse with VYVGART Hytrulo compared to placebo. Detailed data from ADHERE will be presented at an upcoming medical meeting.

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

SHANGHAI, China and CAMBRIDGE, Mass., July 14, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the first patient has been treated in the mainland China portion of the global registrational, Phase 3 FORTITUDE-101 study for bemarituzumab, a potential first-in-class Fc-optimized monoclonal antibody that is designed to block fibroblast growth factors from binding and activating Fibroblast Growth Factor Receptor 2b (FGFR2b), inhibiting several downstream pro-tumor signaling pathways and potentially slowing tumor proliferation. FORTITUDE-101 is a global trial of bemarituzumab in first-line gastric cancer sponsored by Amgen.

News for Zai Lab Ltd. Stock (ZLAB)